- Medvantx recently announced it named Jeremy Gross as chief technology officer of the company
Medvantx — the leading provider of e-commerce and final mile delivery solutions — announced it has named Jeremy Gross as chief technology officer of the company. This newly created position will drive further development of the company’s proprietary e-commerce, pharmacy, and final mile delivery platform.
“Jerry’s unique combination of expertise from the financial technology sector pharmaceutical and logistics industries, is a key addition to Medvantx, and will help our customers navigate a rapidly changing healthcare marketplace,” said Medvantx founder and chief executive officer Robert Feeney.
Gross has more than a 30-year track record of leading development teams and leveraging emerging technologies to create disruptive innovation within biopharma, healthcare and the financial technology industries. Previously, Gross held senior technology, innovation, and incubation leadership roles at Amgen, McKesson, Intuit and JPMorgan.
“Medvantx is one of the early pioneers in the direct-to-patient space and has the experience and infrastructure necessary to support large scale digital transformation strategies for pharmaceutical companies,” added Gross. “I’m thrilled to join the Medvantx team, and to work with leading developers and technology partners to identify and pilot emerging technologies in consumer engagement, machine learning and big data to bring advances to the healthcare industry.”
As the chief technology officer, Gross will lead Medvantx newly created business unit dedicated to advancing the company’s technology platform and identify technology-based solutions for the company’s clients. This unit will be located in San Diego to encourage collaboration with the local digital healthcare and technology community.
Medvantx is licensed in all 50 states and handles over $7.5 billion in prescriptions annually,